Affinage

JDP2

Jun dimerization protein 2 · UniProt Q8WYK2

Length
163 aa
Mass
18.7 kDa
Annotated
2026-04-28
63 papers in source corpus 30 papers cited in narrative 30 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

JDP2 is a bZIP transcription factor that functions as a context-dependent regulator of AP-1 target genes, acting predominantly as a transcriptional repressor but also as a co-activator depending on its dimerization partners and chromatin environment. JDP2 represses transcription by recruiting HDAC3 to target promoters (c-jun, BZLF1, Fshb, CHOP) to deacetylate histones and by directly inhibiting p300-mediated histone acetylation through its N-terminal INHAT domain, while also possessing histone chaperone activity that facilitates nucleosome assembly (PMID:12052888, PMID:16518400, PMID:21525011). JDP2 stability is controlled by JNK-mediated phosphorylation at Thr148, which targets it for proteasomal degradation, and by IRF2-BP1-mediated polyubiquitination (PMID:21463260, PMID:18671972). Beyond repression, JDP2 activates transcription in specific complexes—with β-catenin/PRMT5 to drive glutathione-metabolic genes after genotoxic stress, with AhR/Nrf2 at xenobiotic response elements, and with the progesterone receptor—and Jdp2-knockout mice display osteopetrosis, impaired neutrophil bactericidal activity, elevated FSH with premature reproductive senescence, and resistance to replicative senescence (PMID:31434880, PMID:23200825, PMID:28007961, PMID:19233846).

Mechanistic history

Synthesis pass · year-by-year structured walk · 19 steps
  1. 2001 Medium

    Establishing that JDP2 is a direct transcriptional repressor of p53 through an atypical AP-1 site answered how AP-1 family members could negatively regulate the p53 tumor suppressor pathway.

    Evidence Reporter assays and UV survival assays in mammalian cells

    PMID:11287607

    Open questions at the time
    • Endogenous p53 protein levels not measured
    • No ChIP confirmation of promoter occupancy at time of study
    • No loss-of-function validation
  2. 2001 High

    Identification of Thr148 as the JNK phosphorylation site on JDP2 established that JDP2 is a direct JNK substrate, linking stress-activated MAPK signaling to AP-1 repressor regulation.

    Evidence In vitro kinase assay and T148A mutagenesis with in vivo phosphorylation assay

    PMID:11602244

    Open questions at the time
    • Functional consequence of Thr148 phosphorylation on JDP2 activity not yet determined at this stage
    • No in vivo validation of physiological relevance
  3. 2002 High

    Demonstrating that JDP2 recruits HDAC3 to the c-jun promoter DRE, and that retinoic acid triggers replacement of this complex by p300, established the first chromatin-level mechanism for JDP2-mediated repression and its relief during differentiation.

    Evidence ChIP, Co-IP, and reporter assays in F9 embryonal carcinoma cells

    PMID:12052888

    Open questions at the time
    • Whether HDAC3 recruitment is direct or through an intermediary adaptor was not resolved
    • Genome-wide scope of JDP2/HDAC3 occupancy unknown
  4. 2002 Medium

    Showing that JDP2 promotes myogenic differentiation and cell cycle exit while activating p38 kinase linked JDP2 to muscle lineage commitment beyond its known AP-1 repressor role.

    Evidence Overexpression in C2C12 myoblasts and RD rhabdomyosarcoma cells with differentiation and cell cycle analysis

    PMID:12171923

    Open questions at the time
    • Direct transcriptional targets mediating myogenesis not identified
    • No loss-of-function in muscle cells
    • Mechanism of p38 activation by JDP2 unclear
  5. 2003 High

    Discovery that RANKL induces JDP2 to activate osteoclast-specific genes (TRAP, cathepsin K) and that antisense knockdown blocks osteoclastogenesis established JDP2 as a positive regulator in bone resorption, expanding its role beyond transcriptional repression.

    Evidence Retroviral overexpression, antisense oligonucleotide knockdown, and osteoclastogenesis assays in primary bone marrow cells

    PMID:12707301

    Open questions at the time
    • Dimerization partner enabling activation at these promoters not identified
    • In vivo bone phenotype not yet established
  6. 2006 High

    Reconstitution of JDP2's intrinsic inhibitor-of-HAT (INHAT) activity and histone chaperone function defined a dual chromatin-remodeling mechanism independent of HDAC recruitment, requiring the N-terminal 35 residues and the DNA-binding domain.

    Evidence In vitro histone acetylation assays with recombinant proteins, deletion mutagenesis, and nucleosome assembly assay

    PMID:16518400

    Open questions at the time
    • Structural basis of histone binding not resolved at atomic level
    • Relative contribution of INHAT versus HDAC3 recruitment in vivo at specific loci unknown
  7. 2007 High

    Showing that Jdp2-knockout MEFs have elevated C/EBPδ promoter acetylation and enhanced adipogenesis provided the first genetic evidence that JDP2's histone acetylation-inhibitory activity controls a specific differentiation program in vivo.

    Evidence Jdp2 KO MEFs, hormonal adipocyte induction, ChIP for histone acetylation at C/EBPδ promoter

    PMID:17464331

    Open questions at the time
    • Whether JDP2 uses INHAT or HDAC3 recruitment at the C/EBPδ locus not distinguished
    • Whole-animal adiposity phenotype not reported
  8. 2008 Medium

    Identification of CHOP10 as a leucine-zipper partner that converts JDP2 from a repressor to a TRE-dependent activator, and of JDP2 as a repressor of CHOP transcription via HDAC3 at the AARE, revealed a reciprocal regulatory circuit within the stress-response transcription factor network.

    Evidence Co-IP, EMSA, reporter assays, and amino acid starvation experiments

    PMID:18396163 PMID:18463134

    Open questions at the time
    • Physiological context in which JDP2-CHOP10 activating complex operates in vivo unknown
    • Single-lab findings
  9. 2008 Medium

    Discovery that IRF2-BP1 acts as an E3 ubiquitin ligase for JDP2 identified a post-translational mechanism for controlling JDP2 protein levels through the ubiquitin-proteasome pathway.

    Evidence Epitope-tagging co-purification and ubiquitination assay

    PMID:18671972

    Open questions at the time
    • Specific ubiquitination sites on JDP2 not mapped
    • In vivo significance of IRF2-BP1-mediated degradation not tested
    • Relationship to JNK-mediated degradation pathway not examined
  10. 2009 High

    A cluster of studies using Jdp2-KO MEFs established that JDP2 directly represses cyclin-A2 (controlling proliferation), ATF3 (controlling stress responses), and the p16Ink4a locus (controlling senescence via antagonism of Polycomb-mediated H3K27 methylation), defining JDP2 as a multifaceted gatekeeper of cell fate decisions.

    Evidence Jdp2 KO MEFs with ChIP, reporter assays, proliferation and senescence assays, rescue experiments

    PMID:19233846 PMID:19233874 PMID:20802531

    Open questions at the time
    • How JDP2 antagonizes PRC1/PRC2 binding mechanistically at p16 is unclear
    • Genome-wide occupancy of JDP2 not defined
  11. 2009 Medium

    Identification of retroviral-activated JDP2 isoforms lacking the INHAT domain that cooperate with oncogenic NRAS to drive anchorage-independent growth revealed that loss of JDP2's chromatin-repressive function can contribute to lymphomagenesis.

    Evidence Retroviral insertion analysis in T-cell lymphomas, isoform characterization, anchorage-independent growth assay

    PMID:19502497

    Open questions at the time
    • Whether truncated isoforms act as dominant negatives versus gain-of-function not fully resolved
    • In vivo tumorigenic potential of isoforms alone not tested
  12. 2009 High

    NMR-based mapping of the JDP2-progesterone receptor interaction to the CTE of the PR DNA-binding domain showed that JDP2's bZIP domain can serve as a transcriptional co-activator for a nuclear hormone receptor, establishing structural basis for a non-AP-1 co-activator function.

    Evidence NMR chemical shift perturbation, mutagenesis, and reporter assays

    PMID:19553667

    Open questions at the time
    • Whether this interaction occurs on chromatin at PR target genes in vivo not shown by ChIP
    • Physiological significance in reproductive tissues untested
  13. 2011 High

    Demonstrating that JNK-mediated Thr148 phosphorylation triggers proteasomal degradation of JDP2 closed the loop on JDP2 turnover, showing that the same MAPK pathway that activates AP-1 simultaneously removes its repressor.

    Evidence T148A/T148E mutagenesis, cycloheximide chase, JNK inhibitor and MG132 treatment

    PMID:21463260

    Open questions at the time
    • E3 ligase responsible for JNK-dependent degradation not identified (IRF2-BP1 relationship unclear)
    • In vivo half-life measurements lacking
  14. 2011 High

    Showing that JDP2 represses EBV lytic reactivation by binding the BZLF1 promoter ZII element with HDAC3 extended JDP2's repressive mechanism to antiviral defense.

    Evidence Reporter assay, EMSA, ChIP, siRNA knockdown with viral replication readout

    PMID:21525011

    Open questions at the time
    • Whether JDP2 is relevant to EBV latency control in primary B cells in vivo unknown
    • Other viral targets of JDP2 not explored
  15. 2012 High

    Jdp2-knockout mice exhibited osteopetrosis and defective neutrophil bactericidal function, with ATF3 derepression as the underlying mechanism, providing definitive in vivo genetic evidence for JDP2's role in innate immunity and bone homeostasis.

    Evidence Jdp2 KO mice, skeletal phenotyping, ChIP, bacterial/fungal infection challenge

    PMID:23200825

    Open questions at the time
    • Neutrophil-intrinsic versus microenvironment contributions not fully dissected
    • ATF3 rescue experiment to confirm epistasis not reported
  16. 2016 High

    Demonstrating that JDP2 occupies the Fshb promoter in a complex with c-JUN and is displaced by c-FOS upon GnRH signaling, with Jdp2-null females showing elevated FSH and premature reproductive senescence, established JDP2 as a physiological brake on the reproductive axis.

    Evidence ChIP, Co-IP, Jdp2 KO mouse reproductive phenotyping, hormone measurements

    PMID:28007961

    Open questions at the time
    • Pituitary-specific conditional KO not performed
    • Whether JDP2 regulates other gonadotropin subunits unknown
  17. 2018 High

    JDP2 was shown to directly activate MCL1 transcription and drive T-ALL in a zebrafish transgenic model, establishing JDP2 as a bona fide oncogene in T-cell leukemia that promotes survival through an anti-apoptotic target.

    Evidence shRNA knockdown, ChIP, zebrafish rag2:jdp2 transgenic T-ALL model, steroid treatment

    PMID:29941549

    Open questions at the time
    • Mammalian in vivo validation of JDP2-driven T-ALL not yet reported
    • Whether MCL1 is the sole effector of JDP2 oncogenic activity uncertain
  18. 2019 High

    Discovery that ATM phosphorylates JDP2 to nucleate a β-catenin/PRMT5 chromatin complex that drives H3R2 methylation and subsequent H3K4me3 at glutathione-metabolic gene promoters revealed an activating epigenetic cascade mediated by JDP2 in the DNA damage response.

    Evidence Co-IP, chromatin fractionation, ChIP, histone methylation assays, pharmacological inhibition

    PMID:31434880

    Open questions at the time
    • Specific ATM phosphorylation site(s) on JDP2 not mapped
    • Whether this pathway operates in non-transformed cells in vivo unclear
  19. 2024 Medium

    Two studies expanded JDP2's interactome: JDP2 was shown to physically interact with p53 to enhance its transactivation and reduce MDM2 levels, while IRF2BP2 was found to be recruited to chromatin by the ATF7/JDP2 heterodimer to counteract its gene-activating function in AML cells.

    Evidence Co-IP, reporter assays, CHX chase, ChIP, siRNA/KO in AML cells

    PMID:38473360 PMID:38801077

    Open questions at the time
    • JDP2-p53 interaction validated only by overexpression Co-IP; endogenous interaction not confirmed
    • IRF2BP2-ATF7/JDP2 findings from single lab
    • Genome-wide targets of ATF7/JDP2/IRF2BP2 complex not comprehensively mapped

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include the genome-wide chromatin occupancy map of JDP2, the structural basis of its INHAT and histone chaperone activities at atomic resolution, the identity of the E3 ligase coupling JNK phosphorylation to proteasomal degradation, and the rules determining whether JDP2 functions as a repressor versus activator at a given locus.
  • No genome-wide ChIP-seq or CUT&RUN map published
  • No crystal or cryo-EM structure of JDP2 in complex with histones or partner bZIP proteins
  • E3 ligase for JNK-dependent JDP2 degradation unidentified

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 12 GO:0003677 DNA binding 7 GO:0042393 histone binding 3
Localization
GO:0005634 nucleus 6
Partners
ATF7CHOP10HDAC3IRF2BP1IRF2BP2JUNPGRPRMT5
Complex memberships
ATF7/JDP2/IRF2BP2 complexJDP2/HDAC3 repressor complexβ-catenin/JDP2/PRMT5 activator complex

Evidence

Reading pass · 30 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2002 JDP2 recruits the histone deacetylase 3 (HDAC3) complex to the differentiation response element (DRE) of the c-jun promoter, thereby repressing ATF-2/p300-mediated transactivation and inhibiting retinoic acid-induced differentiation of F9 cells. ChIP assays showed that the JDP2/HDAC3 complex is replaced by the p300 complex in response to RA, accompanied by changes in histone acetylation status. Chromatin immunoprecipitation (ChIP), transient transfection/reporter assays, Co-IP, overexpression in F9 cells Molecular and cellular biology High 12052888
2006 JDP2 directly inhibits p300-mediated acetylation of core histones both in vitro and in vivo, requiring its N-terminal 35 residues and the DNA-binding region. JDP2 also possesses histone-chaperone activity in vitro, enabling nucleosome assembly. In vitro histone acetylation assay with recombinant proteins, deletion mutagenesis, in vivo acetylation assays, nucleosome assembly assay Nature structural & molecular biology High 16518400
2001 JDP2 represses p53 transcription via a conserved atypical AP-1 site in the p53 promoter, thereby increasing cell survival following UV irradiation. Reporter assays, UV survival assays, overexpression in mammalian cells Molecular and cellular biology Medium 11287607
2001 JDP2 is phosphorylated by JNK (c-Jun N-terminal kinase) both in vitro and in vivo at threonine-148; substitution of T148 with alanine blocks JNK-dependent phosphorylation. JDP2 contains a consensus JNK docking site. In vitro kinase assay, site-directed mutagenesis (T148A), in vivo phosphorylation assay FEBS letters High 11602244
2003 JDP2 expression is induced by RANKL in macrophage/osteoclast progenitor cells; overexpression of JDP2 activates TRAP and cathepsin K gene promoters and facilitates TRAP-positive multinuclear osteoclast formation; antisense oligonucleotides to JDP2 suppress osteoclast formation. Retroviral overexpression, transient transfection/reporter assay, antisense oligonucleotide knockdown, osteoclastogenesis assay in primary bone marrow cells The Journal of experimental medicine High 12707301
2012 JDP2 is required in vivo for osteoclastogenesis (Jdp2-/- mice show osteopetrosis) and for neutrophil bactericidal function. JDP2 directly suppresses ATF3 expression via inhibition of histone acetylation at the ATF3 promoter, and ATF3 acts as an inhibitor of neutrophil differentiation. Jdp2 knockout mice, skeletal phenotyping, ChIP assay, in vitro differentiation assay, bacterial/fungal infection challenge Immunity High 23200825
2002 JDP2 expression is induced during myoblast differentiation; ectopic JDP2 expression in C2C12 cells inhibits cell cycle progression, induces spontaneous muscle differentiation, and activates p38 kinase. JDP2 restores myogenic program in rhabdomyosarcoma (RD) cells. Overexpression in C2C12 and RD cells, cell cycle analysis, p38 kinase activity assay, differentiation markers The Journal of biological chemistry Medium 12171923
2007 JDP2 suppresses adipocyte differentiation by inhibiting histone H3 acetylation at the C/EBPdelta gene promoter; Jdp2 KO mouse embryonic fibroblasts show elevated C/EBP family gene expression and increased adipogenesis. Jdp2 knockout MEFs, hormonal adipocyte induction assay, ChIP for histone acetylation at C/EBPdelta promoter, histological analysis Cell death and differentiation High 17464331
2009 JDP2 is directly recruited to an AP-1 site in the cyclin-A2 (Ccna2) promoter to repress its transcription; Jdp2 KO cells have elevated cyclin-A2 mRNA and proliferate faster; reintroduction of JDP2 represses Ccna2 transcription and cell-cycle progression. Jdp2 KO mice/MEFs, ChIP, reporter assay, proliferation assays, reintroduction experiments Oncogene High 20802531
2009 JDP2 represses ATF3 promoter activity through binding to both a consensus ATF/CRE site and a non-consensus ATF3 auto-repression element; JDP2 KO MEFs show elevated ATF3 expression and potentiated ATF3 induction upon serum or ER stress stimulation. Jdp2 KO MEFs, reporter assays, EMSA (implied by promoter binding analysis), Western blotting, in vivo mouse models Nucleic acids research Medium 19233874
2009 JDP2-deficient MEFs are resistant to replicative senescence due to increased H3K27 methylation at the p16(Ink4a) promoter; in the absence of JDP2, Polycomb repressive complexes (PRC-1 and PRC-2) bind efficiently to the p16(Ink4a) promoter and silence it. Conversely, JDP2 overexpression induces p16(Ink4a) and p19(Arf) expression. Jdp2 KO MEFs, ChIP for H3K27 methylation and PRC binding, overexpression, senescence assays (β-galactosidase) The Journal of biological chemistry High 19233846
2008 JDP2 associates with CHOP10 (DDIT3) through leucine zipper interactions; the JDP2-CHOP10 complex strongly activates transcription from promoters containing TPA response elements (TRE) but not CRE elements, with CHOP10's basic domain contributing to DNA binding of the complex. Co-IP, reporter assays, EMSA (in vitro and in vivo DNA binding), luciferase assay, overexpression Nucleic acids research Medium 18463134
2008 JDP2 binds to the CHOP AARE (amino acid response element) in unstimulated cells and represses CHOP transcription in association with HDAC3; upon amino acid starvation, JDP2 binding decreases and CHOP transcription is derepressed. EMSA, reporter assays, ChIP, amino acid deprivation experiments FEBS letters Medium 18396163
2008 IRF2-BP1 (IRF2-binding protein-1) interacts with JDP2 and functions as a ubiquitin E3 ligase for JDP2, enhancing its polyubiquitination. IRF2-BP1 also represses ATF2-mediated transcriptional activation from CRE-containing promoters. Epitope-tagging co-purification, ubiquitination assay, reporter assay FEBS letters Medium 18671972
2011 JDP2 phosphorylation at Thr148 by JNK targets it for proteasomal degradation; T148A substitution stabilizes JDP2, T148E destabilizes it; JNK inhibitor (SP600125) abolishes serum-induced JDP2 degradation; proteasome inhibitor MG132 rescues JDP2 from degradation. Site-directed mutagenesis, kinase inhibitor treatment, proteasome inhibitor (MG132), cycloheximide chase, Western blotting The Biochemical journal High 21463260
2011 JDP2 suppresses Epstein-Barr virus BZLF1 promoter (Zp) activity by binding the ZII cis-element (CREB/ATF/AP-1 site) in association with HDAC3, reducing histone acetylation. Silencing JDP2 by RNAi increased viral early gene products and viral DNA replication. Reporter assay, EMSA, ChIP, mutant virus analysis, siRNA knockdown The Journal of biological chemistry High 21525011
2009 JDP2 acts as a co-activator of the progesterone receptor (PR) by interacting with the carboxyl-terminal extension (CTE) of the PR DNA-binding domain; NMR chemical shift analysis mapped binding to CTE residues; mutations in the CTE reduce JDP2-enhanced PR transcriptional activity. The bZIP domain of JDP2 mediates this interaction. NMR spectroscopy, peptide competition, point mutagenesis, domain swapping, reporter/transactivation assay The Journal of biological chemistry High 19553667
2012 JDP2 transcriptionally represses the Trp53 (p53) promoter via an atypical AP-1 site; JDP2 expression negatively regulates Trp53 expression levels in the context of leukaemogenesis. Transposon insertional mutagenesis screen, reporter assay, expression analysis in KO/OE contexts Oncogene Medium 22370638
2019 Upon genotoxic stress, ATM phosphorylates JDP2, enabling formation of a β-catenin/JDP2/PRMT5 chromatin complex that elicits H3R2me1/H3R2me2s-induced transcriptional activation via WDR5/MLL methyltransferase recruitment and H3K4 methylation at promoters of GSH-metabolic cascade genes to reestablish glutathione/redox homeostasis. Co-IP, chromatin fractionation, ChIP, histone methylation assays, pharmacological inhibition (OICR-9429), genotoxic stress models Nature communications High 31434880
2018 JDP2 directly regulates MCL1 transcription to promote T-ALL cell survival; JDP2 depletion by shRNA leads to apoptosis; JDP2 is capable of initiating T-ALL in transgenic zebrafish (rag2:jdp2) with elevated mcl1 expression and steroid resistance. shRNA knockdown, reporter/ChIP assay, zebrafish transgenic T-ALL model, in vivo steroid treatment The Journal of experimental medicine High 29941549
2016 JDP2 acts as a transcriptional repressor of the FSHβ (Fshb) subunit gene; JDP2 binds the Fshb promoter at an AP-1 site in a complex with c-JUN; GnRH treatment induces c-FOS to replace JDP2 as the c-JUN binding partner, forming transcriptionally active AP-1. JDP2 null female mice show elevated FSH, early puberty, and premature reproductive senescence. ChIP, reporter assays, Co-IP, Jdp2 KO mouse phenotyping, hormone measurements The Journal of biological chemistry High 28007961
2014 Doublecortin-like protein kinase (DCLK) kinase domain interacts with JDP2 (identified by yeast two-hybrid) and phosphorylates JDP2 efficiently only when histone is present; nuclear translocation of DCLK kinase domain occurs under hyperosmotic stress conditions. Yeast two-hybrid, in vitro kinase assay, nuclear translocation imaging Biochemical and biophysical research communications Low 24582561
2019 JDP2 directly regulates ATF3 expression; in ATF3/JDP2 double-KO fibroblasts, SDF-1 secretion is elevated and drives tumor growth and vascular perfusion; ATF3 and JDP2 jointly regulate SDF-1 transcription in fibroblasts. Double KO mouse model, conditioned medium assay, tumor implantation, SDF-1 depletion rescue Oncogene Medium 30670778
2021 JDP2 forms a transcriptional complex with AhR-ARNT and Nrf2-sMAF at DRE and ARE cis-elements of the AhR promoter; Jdp2 is required for AhR promoter activation in response to DMSO; Co-IP and ChIP showed Jdp2 integrates into these phase I/II transcription factor complexes. Co-immunoprecipitation, ChIP, reporter assays, Jdp2 KO MEFs, ROS measurement Cell biology and toxicology Medium 33723743
2020 In Jdp2-deficient granule cell progenitors (GCPs), a complex of p21Cip1 and Nrf2 binds to antioxidant response elements of the Slc7a11 promoter, increasing xCT/Slc7a11 expression and glutathione levels, thereby conferring resistance to ROS-mediated apoptosis. Jdp2 KO mice, primary GCP cultures, ChIP, glutathione measurement, ROS assay, apoptosis assay Scientific reports Medium 32188872
2017 CGRP suppresses β-glucan-induced inflammation and osteoclast multinucleation via direct suppression of NF-κB p65 by JDP2 (a transcriptional repressor) and inhibition of actin polymerization; Dectin-1/TRP channel signaling in Nav1.8+ nociceptors drives this pathway. Nociceptor ablation, TRPV1/TRPA1 KO mice, β-glucan injection model, CGRP treatment, osteoclast multinucleation assay Cell reports Medium 28658621
2024 JDP2 interacts directly with p53 via its C-terminal domain and enhances p53 transactivation; JDP2 decreases MDM2 levels, thereby reversing MDM2-induced p53 repression. JDP2 also slightly enhances p53 protein stability in CHX chase experiments. Co-IP, reporter assay (p53-responsive luciferase), CHX chase, overexpression/knockdown, domain mapping Cancers Medium 38473360
2024 IRF2BP2 interacts with the AP-1 heterodimer ATF7/JDP2 and is recruited to chromatin by this dimer; IRF2BP2 counteracts the gene-activating function of ATF7/JDP2, and its loss leads to inflammatory pathway overactivation and reduced proliferation in AML cells. Co-IP, ChIP, siRNA/KO loss-of-function, proliferation assay, gene expression analysis Nucleic acids research Medium 38801077
2020 JDP2 directly activates PDE4B transcription; ChIP and dual-luciferase reporter assays confirmed JDP2 binding to the PDE4B promoter; JDP2 overexpression upregulates PDE4B and exacerbates hypoxia/reoxygenation-induced cardiomyocyte injury. Dual-luciferase reporter assay, ChIP, overexpression/knockdown in H9c2 cells, H/R model Experimental and therapeutic medicine Medium 35401806
2009 Retroviral insertion into Jdp2 intron 2 in T-cell lymphomas activates non-canonical Jdp2 RNA subspecies generating protein isoforms lacking the INHAT (inhibitor of histone acetyltransferase) domain; these shorter isoforms localize to the nucleus and, when co-expressed with oncogenic NRAS, increase anchorage-independent growth. Northern blot, qRT-PCR, promoter analysis, nuclear localization imaging, anchorage-independent growth assay Nucleic acids research Medium 19502497

Source papers

Stage 0 corpus · 63 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2017 Nociceptors Boost the Resolution of Fungal Osteoinflammation via the TRP Channel-CGRP-Jdp2 Axis. Cell reports 92 28658621
2002 JDP2, a repressor of AP-1, recruits a histone deacetylase 3 complex to inhibit the retinoic acid-induced differentiation of F9 cells. Molecular and cellular biology 86 12052888
2003 Jun dimerization protein 2 (JDP2), a member of the AP-1 family of transcription factor, mediates osteoclast differentiation induced by RANKL. The Journal of experimental medicine 75 12707301
2006 Regulation of histone acetylation and nucleosome assembly by transcription factor JDP2. Nature structural & molecular biology 69 16518400
2012 The transcription factor Jdp2 controls bone homeostasis and antibacterial immunity by regulating osteoclast and neutrophil differentiation. Immunity 67 23200825
2001 AP-1 repressor protein JDP-2: inhibition of UV-mediated apoptosis through p53 down-regulation. Molecular and cellular biology 61 11287607
2002 Induction of terminal differentiation by the c-Jun dimerization protein JDP2 in C2 myoblasts and rhabdomyosarcoma cells. The Journal of biological chemistry 52 12171923
2007 JDP2 suppresses adipocyte differentiation by regulating histone acetylation. Cell death and differentiation 50 17464331
2010 Suppression of cell-cycle progression by Jun dimerization protein-2 (JDP2) involves downregulation of cyclin-A2. Oncogene 49 20802531
2019 Induction of Pluripotent Stem Cells from Mouse Embryonic Fibroblasts by Jdp2-Jhdm1b-Mkk6-Glis1-Nanog-Essrb-Sall4. Cell reports 43 31216469
2001 The AP-1 repressor, JDP2, is a bona fide substrate for the c-Jun N-terminal kinase. FEBS letters 43 11602244
2010 The AP-1 repressor protein, JDP2, potentiates hepatocellular carcinoma in mice. Molecular cancer 42 20214788
2009 The ubiquitously expressed bZIP inhibitor, JDP2, suppresses the transcription of its homologue immediate early gene counterpart, ATF3. Nucleic acids research 42 19233874
2019 Genotoxic stress-triggered β-catenin/JDP2/PRMT5 complex facilitates reestablishing glutathione homeostasis. Nature communications 40 31434880
2013 Inhibition of AP-1 signaling by JDP2 overexpression protects cardiomyocytes against hypertrophy and apoptosis induction. Cardiovascular research 37 23612584
2008 TRE-dependent transcription activation by JDP2-CHOP10 association. Nucleic acids research 35 18463134
2009 JDP2 (Jun Dimerization Protein 2)-deficient mouse embryonic fibroblasts are resistant to replicative senescence. The Journal of biological chemistry 33 19233846
2020 Down-regulated lncRNA AGAP2-AS1 contributes to pre-eclampsia as a competing endogenous RNA for JDP2 by impairing trophoblastic phenotype. Journal of cellular and molecular medicine 29 32150333
2013 Preeclamptic plasma induces transcription modifications involving the AP-1 transcriptional regulator JDP2 in endothelial cells. The American journal of pathology 29 24120378
2009 A progesterone receptor co-activator (JDP2) mediates activity through interaction with residues in the carboxyl-terminal extension of the DNA binding domain. The Journal of biological chemistry 29 19553667
2018 JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. The Journal of experimental medicine 26 29941549
2019 ATF3 and JDP2 deficiency in cancer associated fibroblasts promotes tumor growth via SDF-1 transcription. Oncogene 24 30670778
2016 c-JUN Dimerization Protein 2 (JDP2) Is a Transcriptional Repressor of Follicle-stimulating Hormone β (FSHβ) and Is Required for Preventing Premature Reproductive Senescence in Female Mice. The Journal of biological chemistry 24 28007961
2005 Tumor model-specific proviral insertional mutagenesis of the Fos/Jdp2/Batf locus. Virology 24 15913695
2011 Involvement of Jun dimerization protein 2 (JDP2) in the maintenance of Epstein-Barr virus latency. The Journal of biological chemistry 23 21525011
2005 Depletion of the AP-1 repressor JDP2 induces cell death similar to apoptosis. Biochimica et biophysica acta 23 16026868
2012 Jdp2 downregulates Trp53 transcription to promote leukaemogenesis in the context of Trp53 heterozygosity. Oncogene 22 22370638
2008 Role of the repressor JDP2 in the amino acid-regulated transcription of CHOP. FEBS letters 22 18396163
2008 IRF2-binding protein-1 is a JDP2 ubiquitin ligase and an inhibitor of ATF2-dependent transcription. FEBS letters 20 18671972
2009 Activation of alternative Jdp2 promoters and functional protein isoforms in T-cell lymphomas by retroviral insertion mutagenesis. Nucleic acids research 19 19502497
2018 JDP2 overexpression provokes cardiac dysfunction in mice. Scientific reports 18 29769710
2019 JDP2 and ATF3 deficiencies dampen maladaptive cardiac remodeling and preserve cardiac function. PloS one 15 30818334
2011 Phosphorylation of JDP2 on threonine-148 by the c-Jun N-terminal kinase targets it for proteosomal degradation. The Biochemical journal 15 21463260
2010 Histone chaperone Jun dimerization protein 2 (JDP2): role in cellular senescence and aging. The Kaohsiung journal of medical sciences 15 20950777
2021 Dimethyl sulfoxide stimulates the AhR-Jdp2 axis to control ROS accumulation in mouse embryonic fibroblasts. Cell biology and toxicology 13 33723743
2011 The effect of JDP2 and ATF2 on the epithelial-mesenchymal transition of human pancreatic cancer cell lines. Pathology oncology research : POR 13 22109562
2014 Nuclear translocation of doublecortin-like protein kinase and phosphorylation of a transcription factor JDP2. Biochemical and biophysical research communications 11 24582561
2012 JDP2 inhibits the epithelial-to-mesenchymal transition in pancreatic cancer BxPC3 cells. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 11 22535371
2023 Jdp2 is a spatiotemporal transcriptional activator of the AhR via the Nrf2 gene battery. Inflammation and regeneration 10 37596694
2020 Jdp2-deficient granule cell progenitors in the cerebellum are resistant to ROS-mediated apoptosis through xCT/Slc7a11 activation. Scientific reports 10 32188872
2020 Structural, Pro-Inflammatory and Calcium Handling Remodeling Underlies Spontaneous Onset of Paroxysmal Atrial Fibrillation in JDP2-Overexpressing Mice. International journal of molecular sciences 9 33265909
2015 Host JDP2 expression in the bone marrow contributes to metastatic spread. Oncotarget 8 26497998
2003 Sequence specific transcription factor, JDP2 interacts with histone and inhibits p300-mediated histone acetylation. Nucleic acids research. Supplement (2001) 8 14510502
2025 The AHR-NRF2-JDP2 gene battery: Ligand-induced AHR transcriptional activation. Biochemical pharmacology 7 39855429
2021 JDP2, a Novel Molecular Key in Heart Failure and Atrial Fibrillation? International journal of molecular sciences 7 33923401
2020 JDP2 is directly regulated by ATF4 and modulates TRAIL sensitivity by suppressing the ATF4-DR5 axis. FEBS open bio 7 33108704
2014 Cloning and characterization of the mouse JDP2 gene promoter reveal negative regulation by p53. Biochemical and biophysical research communications 7 25026555
2002 Transcriptional regulation of the c-jun gene by AP-1 repressor protein JDP2 during the differentiation of F9 cells. Nucleic acids research. Supplement (2001) 7 12903123
2024 IRF2BP2 counteracts the ATF7/JDP2 AP-1 heterodimer to prevent inflammatory overactivation in acute myeloid leukemia (AML) cells. Nucleic acids research 6 38801077
2021 Deletion of Jdp2 enhances Slc7a11 expression in Atoh-1 positive cerebellum granule cell progenitors in vivo. Stem cell research & therapy 6 34187574
2023 Opposing effects of KDM6A and JDP2 on glucocorticoid sensitivity in T-ALL. Blood advances 4 36897249
2018 Deletion of JDP2 improves neurological outcomes of traumatic brain injury (TBI) in mice: Inactivation of Caspase-3. Biochemical and biophysical research communications 4 30217453
2004 Histone modification activities of JDP2 associated with retinoic acid-induced differentiation of F9 cells. Nucleic acids symposium series (2004) 4 17150542
2024 Trans-differentiation of Jdp2-depleted Gaba-receptor-positive cerebellar granule cells to Purkinje cells. Cell death discovery 3 39695141
2023 Palmitic acid-induced microRNA-143-5p expression promotes the epithelial-mesenchymal transition of retinal pigment epithelium via negatively regulating JDP2. Aging 3 37179125
2022 Transcription factor JDP2 activates PDE4B to participate in hypoxia/reoxygenation-induced H9c2 cell injury. Experimental and therapeutic medicine 3 35401806
2022 ITGBL1 transcriptionally inhibited by JDP2 promotes the development of pancreatic cancer through the TGF-beta/Smad pathway. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 3 35584452
2024 Jun Dimerization Protein 2 (JDP2) Increases p53 Transactivation by Decreasing MDM2. Cancers 2 38473360
2025 Down-Regulated JDP2 Attenuated Trophoblast Invasion and Migration in Preeclampsia by Inhibiting Epithelial-Mesenchymal Transition through the Wnt/β-Catenin Pathway. Current protein & peptide science 1 39171471
2024 Vulnerability of Antioxidant Drug Therapies on Targeting the Nrf2-Trp53-Jdp2 Axis in Controlling Tumorigenesis. Cells 1 39404411
2025 Maintenance and Reversibility of Paroxysmal Atrial Fibrillation in JDP2 Overexpressing Mice. Cells 0 40710332
2020 Author Correction: Jdp2-deficient granule cell progenitors in the cerebellum are resistant to ROS-mediated apoptosis through xCT/Slc7a11 activation. Scientific reports 0 32528039
2010 Epigenetic regulation of p16Ink4a and Arf by JDP2 in cellular senescence. Biomolecular concepts 0 25961985